Product Image

Contributor Information

  • Name Karen Pulford
  • Institute University of Oxford

Tool Details

  • Tool name: Anti-CD19 [PDR134]
  • Alternate names: CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
  • Clone: PDR134
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IF ; IP ; WB
  • Description: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by progenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic lymphocytic leukemia and non-Hodgkin’s lymphoma). Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
  • Immunogen: Pokeweek-stimulated Daudi and Raji cells
  • Isotype: IgM
  • Research area: Cancer; Cell signaling and signal transduction; Immunology; Stem cell biology
  • Myeloma used: P3/NS1/1-Ag4.1

  • For Research Use Only

Target Details

  • Target: CD19
  • Target background: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by progenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic lymphocytic leukemia and non-Hodgkin's lymphoma). Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.

Application Details

  • Application: FACS ; IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-L1CAM [UJ181.4]

#151179
Product Image

Anti-Integrin alpha3 (CD49c) monoclonal antibody [KU44.22B]

#161583
Product Image

Anti-Serca2 ATPase [IIH11]

#153722

References

  • •  Sato S and Tedder TF. 1997. CD19 Workshop Panel report. In Kishimoto T, et al (eds) Leucocyte Typing VI, Garland Publishing Inc., New York and London, p 133-135
  • •  Tedder TF et al. 1995. B-cell antigens: section report. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 1, Oxford University Press, Oxford, New York and Tokyo, p 491.